A new Antimicrobial Resistance (AMR) Action Fund will inject nearly US $1 billion into the collapsing antibiotic development pipeline, aiming to bring two to four new antibiotics to patients by 2030. The investment, organized by the International Federation of Pharmaceutical Manufacturers & Associations and 23 different pharma companies, is the biggest single investment in antibiotic […] Continue reading ->
BREAKING – The United States on Tuesday gave formal notice to the United Nations and the US Congress that it intends to withdraw from the World Health Organization as of  6 July 2021, following President Donald Trump’s announcement after the World Health Assembly on 18 May. The administration first notified the United Nations, and sent […] Continue reading ->
A growing bloc of aerosol scientists, epidemiologists, and infectious disease experts are urging the World Health Organization to acknowledge that particles containing SARS-CoV-2, the virus that causes COVID-19, can remain suspended in the air for hours and be inhaled, potentially representing another route of transmission. Some 239 scientists from around the world urged the WHO […] Continue reading ->
The United States has secured almost all of Gilead Sciences’ projected production of remdesivir – an antiviral that was shown to reduce hospitalization times for COVID-19 patients- for the next three months. US Health and Human Services (HHS) has secured 100 percent of Gilead’s projected production for July (94,200 treatment courses), 90 percent of production […] Continue reading ->
A COVID-19 vaccine candidate under development by pharma giant Pfizer and biotech firm BioNTech showed promise in interim results released Wednesday. The vaccine candidate, BNT162b1, was able to induce the formation of antibodies that neutralized SARS-CoV-2, the virus that causes COVID-19, in all participants who received doses between 10ug to 30ug, according to a report […] Continue reading ->
A six-vial five-day course of remdesivir – a promising COVID-19 treatment – will be priced at US $2340, or $390 per vial for developed countries, Gilead Sciences Chief Executive Officer Daniel O’Day wrote in an open letter on Monday. “Earlier hospital discharge [thanks to treatment by remdesivir] would result in hospital savings of approximately $12,000 […] Continue reading ->